Loading...
OTC Markets
Totals
Securities
12,304
Dollar Vol
$2.5B
Share Vol
3.8B
Trades
319,611

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

ADIA
Adia Nutrition, Inc.

Common Stock

0.068

-0.002

-2.86%

No Inside Bid / Offer

Delayed (15 Min) Trade Data: 12:00am 06/13/2025

0.064

0.058 - 0.07

40,000

Market Cap calculated only for this class of securities.

5,467,519

Real-Time Level 2 Quote
Bid
Ask
MPID
MPID
Bid Price
Bid Price
Size
Size
Time
Time
MPID
MPID
Ask Price
Ask Price
Size
Size
Time
Time
Trade Data
Date
Date
Timestamp
Timestamp
Price
Price
$ Change
$ Change
Volume
Volume
06/13/202512:39:37
0.068
0.0110,000
06/13/202512:39:37
0.058
-0.0110,000
06/13/202511:11:31
0.07
0.0110,000
06/13/202511:11:16
0.064
-0.0110,000
06/11/202510:29:23
0.07
0.003,500
More Irregular/odd lot trades, which are not considered for the Open, High, Low or Closing prices, are not shown in trade data table.
Company Description
Adia Nutrition Inc. (OTC Pink: ADIA), based in Winter Park, Florida, is a publicly traded company transforming healthcare and supplementation. Its medical and supplement divisions aim to boost health and vitality through innovation and expansion. Adia Med leads with a nationwide rollout of satellite locations offering Umbilical Cord Stem Cell (UCB-SC) and exosome treatments, like AdiaVita from Adia Labs LLC, with 100 million stem cells and 3 trillion exosomes per unit. These therapies address chronic inflammation, autoimmune disorders, and orthopedic issues. Partnerships with top medical entities help expand access to regenerative medicine. Full clinics with apheresis machines will also offer Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for conditions like Multiple Sclerosis and Therapeutic Plasma Exchange (TPE) for diseases like Alzheimer's. The supplement division offers premium organic products, boosted by a 2024 partnership with Cement Factory LLC., including Biolete coffee with collagen and mushrooms. Adia's revenue comes from service fees, product sales, and equity stakes, while pushing for standardized stem cell protocols with FDA-approved labs. Through this dual strategy, Adia is redefining healthcare and promoting wellness nationwide.
Videos

This company has not added any videos

OTCQB Venture Market Logo
Joined OTCQB 05/2025
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
The Company’s board of directors includes at least two Independent Directors.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.